Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,055 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
Herceptin, NeuVax vaccine, GM-CSF
Drug
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

NCT07649161
Conditions
Healthy Adult
Interventions
Niagen®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 8 more
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Duarte, California • Jacksonville, Florida • Greenlawn, New York
Terminated Phase 1Phase 2 Interventional Results available

Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

NCT03689894
Conditions
Chronic Graft-versus-host-disease
Interventions
Ibrutinib, Rituximab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Active, not recruiting Not applicable Interventional

Dine and DASH Into Wellness Pilot Study

NCT07175896
Conditions
Chronic Kidney Disease, Diet Interventions, Disease Prevention
Interventions
Immediate delivery of low-sodium DASH (Dietary Approaches to Stop Hypertension) diet group coaching plus hand-on cooking program, Delayed delivery of low-sodium DASH (Dietary Approaches to Stop Hypertension) diet group coaching plus hand-on cooking program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 59 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ulcerative Colitis (UC)
Interventions
Ulcerative Colitis Diet, Antibiotic cocktail
Other · Drug
Lead sponsor
Prof. Arie Levine
Government
Eligibility
8 Years to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Superficial Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Kansas City, Kansas • Minneapolis, Minnesota • Rochester, Minnesota
Conditions
Carcinoma, Small Cell
Interventions
Pomalidomide, Cisplatin, Etoposide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Cleveland, Ohio • Hershey, Pennsylvania • Dallas, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Contingency Management, Quitting Smoking, and ADHD

NCT02266784
Conditions
Cigarette Smoking, Smoking Cessation
Interventions
Contingency Management (CM), Transdermal nicotine skin patches (i.e. Habitrol), Supportive Counseling
Behavioral · Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Glioblastoma
Interventions
Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neuroblastoma
Interventions
124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Miguel Pampaloni
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Post Traumatic Stress Disorders, Unsafe Sex, Substance Use Disorders
Interventions
Cognitive Processing Therapy-Cognitive
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Toppenish, Washington
Conditions
Leukemia
Interventions
etoposide, mitoxantrone hydrochloride, valspodar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
50
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Conditions
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Venous Ulcers
Interventions
Nitric Oxide - same dose 6 wks, Nitric Oxide modified treatment
Drug
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery, 3-dimensional conformal radiation therapy, ifosfamide
Drug · Other · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more
Conditions
Chemotherapy-related Cognitive Impairment
Interventions
Low-Intensity Walking Intervention, Control Group Intervention
Behavioral
Lead sponsor
Ellis Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Schenectady, New York